Key result
Esaxerenone administered before cardioplegic arrest significantly improved the recovery of left ventricular developed pressure compared to control (62.1% vs 50.8%; p<0.05).
Why the study?
Esaxerenone attenuates global ischemia-induced myocardial damage and coronary endothelial dysfunction, but whether it exerts cardioprotective effects against cardioplegic arrest was unknown.
Does esaxerenone improve recovery of LVDP and reduce troponin T leakage in isolated rat hearts subjected to cardioplegic arrest?
RCT (n=12)
randomly allocated
Does esaxerenone improve recovery of LVDP and reduce troponin T leakage in isolated rat hearts subjected to cardioplegic arrest?
Absolute Event Rate: 62.1% vs 50.8%
p-value: p=<0.05
Esaxerenone administered before cardioplegic arrest enhances cardioprotection and reduces myocardial damage in isolated rat hearts.
Esaxerenone may confer experimental cardioprotection during cardioplegic arrest; leaves open translation to human cardiac surgery.
PURPOSE: Esaxerenone, a mineralocorticoid receptor blocker, attenuates global ischemia-induced myocardial damage and coronary endothelial dysfunction. This study aimed to determine whether esaxerenone exerted cardioprotective effects against cardioplegic arrest in Wistar rat hearts. METHODS: Isolated male Wistar rat hearts aerobically perfused via the Langendorff method for 20 min were randomly allocated to the Control (n = 6; perfused for an additional 10 min and subjected to no treatment) or Esax (n = 6; perfused with 0.1 μmol/L esaxerenone in perfusate for 10 min before ischemia) groups. Hearts in both groups were perfused with St. Thomas' Hospital No. 2 solution (STH2) for 2 min and subjected to 28 min of global ischemia. The recovery of left ventricular developed pressure (LVDP) and total troponin T leakage were measured after reperfusion. RESULTS: The final recovery of LVDP (expressed as a percentage of pre-ischemic value) in the Control and Esax groups was 50.8 ± 3.5% and 62.1 ± 5.6%, respectively (p <0.05, Esax vs. Control). The total troponin T leakage in the Control and Esax groups was 138.8 ± 18.5 ng/g heart wt and 74.3 ± 18.6 ng/g heart wt, respectively (p <0.05, Esax vs. Control). CONCLUSION: The administration of esaxerenone before cardioplegic arrest enhanced the cardioprotective effect exerted by STH2.
No takes yet. Share an insight, caveat, or question.
Fujii et al. (2024) conducted an RCT in Cardioplegic arrest (n=12). Esaxerenone vs. Control (no treatment) was evaluated on Recovery of left ventricular developed pressure (LVDP) (p=<0.05). Esaxerenone administered before cardioplegic arrest significantly improved the recovery of left ventricular developed pressure compared to control (62.1% vs 50.8%; p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: